The CR rate was consistent across subgroups including men and women, patients with and without papillary disease, and ...

Johnson & Johnson (J&J) has reported more data supporting the efficacy of its intravesical drug release system TAR-200 in ...

Chris Cotton is raising money for cancer centers after being told the day after his 50th birthday that what he thought was a ...

In a study from Dr. Zlotta’s group published in 2025 in the Journal of Urology, 1 they suggest that better tools are needed to minimize interobserver variability in pathological grading. This is ...

CG Oncology shared new Phase 3 trial results showing durable responses and strong patient compliance in high-risk bladder ...

A dad who thought he had a UTI was diagnosed with stage four bladder cancer and given 24 months to live. Dad-of-two Chris ...

TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk ...

UroGen Pharma reports strong long-term data for Jelmyto and UGN-102 in cancer studies and shares promising early results for ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer ...

Among patients with non-muscle-invasive bladder cancer (NMIBC), neoadjuvant treatment with mitomycin C prior to transurethral ...

With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...

Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.